Non-Hodgkin's Lymphomas, version 3.2012: Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 10, Issue 12, 2012, Pages 1487-1498

  Zelenetz, Andrew D ^a   Wierda, William G ^b   Abramson, Jeremy S ^c   Advani, Ranjana H ^d   Andreadis, C Babis ^e   Bartlett, Nancy ^f   Bellam, Naresh ^g   Byrd, John C ^h   Czuczman, Myron S ⁱ   Fayad, Luis ^b   Glenn, Martha J ^j   Gockerman, Jon P ^k   Gordon, Leo I ^l   Harris, Nancy Lee ^b   Hoppe, Richard T ^c   Horwitz, Steven M ^a   Kelsey, Christopher R ^k   Kim, Youn H ^c   Krivacic, Susan ^x   LaCasce, Ann S ^m   Nademanee, Auayporn ⁿ   Porcu, Pierluigi ^g   Press, Oliver ^o   Pro, Barbara ^p   Reddy, Nishitha ^q   Sokol, Lubomir ^r   Swinnen, Lode ^s   Tsien, Christina ^t   Vose, Julie M ^u   Yahalom, Joachim ^a   Zafar, Nadeem ^v   Naganuma, Maoko ^w   Dwyer, Mary A ^w   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d STANFORD CANCER INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BARNES JEWISH HOSPITAL   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ ROSWELL PARK CANCER INSTITUTE   (United States)

^j UNIVERSITY OF UTAH   (United States)

^k DUKE CANCER INSTITUTE   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m Dana Farber Brigham and Women's Cancer Center   (United States)

ⁿ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^o SEATTLE CANCER CARE ALLIANCE   (United States)

^p FOX CHASE CANCER CENTER   (United States)

^q VANDERBILT INGRAM CANCER CENTER   (United States)

^r H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^s JOHNS HOPKINS UNIVERSITY   (United States)

^t UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^u NEBRASKA MEDICAL CENTER   (United States)

^v UNIVERSITY OF TENNESSEE CANCER INSTITUTE   (United States)

^w National Comprehensive Cancer Network   (United States)

^x NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; BENDAMUSTINE; CARBOPLATIN; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; OFATUMUMAB; OXALIPLATIN; PENTOSTATIN; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONSOLIDATION CHEMOTHERAPY; CYTOGENETICS; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EVIDENCE BASED PRACTICE; FOLLICULAR LYMPHOMA; FOLLOW UP; FRAIL ELDERLY; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; LARGE CELL LYMPHOMA; LEUKEMIA REMISSION; MANTLE CELL LYMPHOMA; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 84871444162     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2012.0155     Document Type: Review

References (34)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
3. National Cancer Institute. SEER Stat Fact Sheets: Chronic Lymphocytic Leukemia. Bethesda, MD: 2012. Available at: http://seer.cancer.gov/statfacts/ html/clyl.html. Accessed August 2012.
4. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-1174.
5. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756-1765.
6. Eichhorst B, Goede V, Hallek M. Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:171-178.
7. Eichhorst BF, Busch R, Stilgenbauer S, et al. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009;114:3382-3391.
8. Foa R, Alietti A, Guarini A, et al. A phase II study of chlorambucil rituximab (CLB-R) followed by R maintenance vs observation in elderly patients with previously untreated chronic lymphocytic leukemia (CLL): induction phase results [abstract]. Haematologica 2011;96(Suppl 2):Abstract 532.
9. Foa R, Ciolli S, Di Raimondo F, et al. Rituximab plus chlorambucil as initial treatment for elderly patients with chronic lymphocytic leukemia (CLL): effect of pre-treatment biological characteristics and gene expression patterns on response to treatment [abstract]. Blood 2011;118:Abstract 294.
10. Hillmen P, Gribben JG, Follows GA, et al. Rituximab plus chlorambucil (R-Chlorambucil) as first-line treatment for chronic lymphocytic leukaemia (CLL): final analysis of an open-label phase II study [abstract] Ann Oncol 2011;22(Suppl 4):Abstract 120.
11. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309-317.
12. Strumberg D, Harstrick A, Doll K, et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996;7:415-421.
13. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-4384.
14. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine induces higher remission rates, prolongs progression free survival as well as time to next treatment, and improves overall survival for patients in complete remission without compromising quality of life when compared to chlorambucil in first line treatment of chronic lymphocytic leukemia [abstract]. Blood 2010;116:Abstract 2449.
15. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol 2012;159:67-77.
16. Knauf WU, Lissitchkov T, Aldaoud A, et al. Bendamustine in the treatment of chronic lymphocytic leukemia-consistent superiority over chlorambucil in elderly patients and across clinically defined risk groups [abstract]. Blood 2009;114:Abstract 2367.
17. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30:3209-3216.
18. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011:3559-3566.
19. Oh YK, Ha CS, Samuels BI, et al. Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies. Radiology 1999;210:483-486.
20. Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27:1781-1787.
21. Guppy AE, Tebbutt NC, Norman A, Cunningham D. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:123-125.
22. Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol 2006;17:909-913.
23. Petrausch U, Samaras P, Haile SR, et al. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol 2010;21:1694-1698.
24. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-7023.
25. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687-2693.
26. Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009;27:6101-6108.
27. Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010;21:133-139.
28. Ritchie DS, Seymour JF, Grigg AP, et al. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 2007;86:101-105.
29. Pott C, Hoster E, Beldjord K, et al. R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL younger intergroup trial of the European MCL Network [abstract]. Blood 2010;116:Abstract 965.
30. Lacasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012;119:2093-2099.
31. Chang JE, Peterson C, Choi S, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol 2011;155:190-197.
32. Kahl BS, Longo WL, Eickhoff JC, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006;17:1418-1423.
33. Kluin-Nelemans JC, Hoster E, Walewski J, et al. R-CHOP versus R-FC followed by maintenance with rituximab versus interferonalfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma [abstract]. Blood 2011;118:Abstract 439.
34. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012;367:52-531.